Sign In
Buy ADMP
$0.775
+0 (+0%)
At Close: Dec 06, 2023
Adamis Pharmaceuticals Provides Business Update
07:30am, Tuesday, 01'st Jun 2021
NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19 NDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation i
Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ
04:04pm, Friday, 28'th May 2021
SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, al
LOS ANGELES--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
11:30am, Wednesday, 26'th May 2021
LOS ANGELES--(BUSINESS WIRE)---- $ADMP #investors--The Law Offices of Frank R. Cruz Announces Investigation of Adamis Pharmaceuticals Corporation (ADMP) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)---- $ADMP #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) (NA
Boston, Massachusetts--(Newsfile Corp. - May 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Adamis Phar
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
04:05pm, Monday, 17'th May 2021
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be he
Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose
09:32am, Monday, 17'th May 2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose. "Based on
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
07:30am, Monday, 17'th May 2021
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, al
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
07:30am, Wednesday, 12'th May 2021
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, al
ADMP Stock: From $0.76 To $1.07 (40.07% Increase) Explanation
04:13pm, Tuesday, 04'th May 2021
The stock price of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) increased from $0.76 to $1.07 (up 40.07%). This is why it happened.
Adamis Pharmaceuticals: Upcoming Catalysts Support Speculative Buy
01:30pm, Wednesday, 14'th Apr 2021
Adamis Pharmaceuticals has a strong list of potential catalysts that may have a positive impact on the share price. The recent sell-off has provided me an opportunity to accumulate. Adamis has a histo
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
04:03pm, Tuesday, 13'th Apr 2021
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,
Adamis Pharma To Resubmit Zimhi US Application For Opioid Overdose Soon
10:28am, Monday, 12'th Apr 2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has provided an update on its marketing application's status seeking approval for Zimhi's high-dose naloxone injection product to treat opioid ove
Adamis Pharmaceuticals Provides an Update on ZIMHI™
07:00am, Monday, 12'th Apr 2021
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company's New Drug Application (NDA) relating to its ZIMHI
